ALLMedicine™ Diabetic Ketoacidosis Center

Sep 17th, 2020 - Diabetic ketoacidosis (DKA) is an acute metabolic complication characterized by hyperglycemia, ketones in blood or urine, and acidosis. Assess the characteristics of patients hospitalized for DKA, identify triggers for DKA and evaluate the long-te...

Sep 16th, 2020 - The International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2018 for management of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state 1, 2 provide comprehensive guidance for mana...

Sep 15th, 2020 - To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. Data from two identically designed, 52-week, randomized st...

Sep 14th, 2020 - Diabetic ketoacidosis (DKA) is a medical emergency with a high mortality rate and is associated with severe metabolic acidosis and dehydration. DKA patients have an increased risk of arterial and venous thromboembolism, however little is known abo...

Sep 8th, 2020 - Current guidelines recommend withholding sodium-glucose cotransporter 2 inhibitors perioperatively due to concerns of euglycaemic diabetic ketoacidosis. However, such guidelines are largely based on case reports and small case series, many extrapo...

Jun 27th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia...

Apr 10th, 2018 - The biochemical criteria for the diagnosis of diabetic ketoacidosis (DKA) are: Hyperglycemia (blood glucose >11 mmol/L [≈200 mg/dL]) Venous pH <7. 3 or serum bicarbonate <15 mmol/L Ketonemia (blood ß-hydroxybuyrate ≥3 mmol/L) or moderate or large k.

May 19th, 2015 - Hyperglycaemic hyperosmolar state (HHS) is a medical emergency, which differs from diabetic ketoacidosis (DKA) and requires a different approach. The present article summarizes the recent guidance on HHS that has been produced by the Joint British...

Jul 21st, 2014 - ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state.|2014|Wolfsdorf JI,Allgrove J,Craig ME,Edge J,Glaser N,|trends,adverse effects,blood,complications,drug therapy,therapy,blood,complicatio...

Sep 17th, 2020 - Diabetic ketoacidosis (DKA) is an acute metabolic complication characterized by hyperglycemia, ketones in blood or urine, and acidosis. Assess the characteristics of patients hospitalized for DKA, identify triggers for DKA and evaluate the long-te...

Sep 16th, 2020 - The International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2018 for management of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state 1, 2 provide comprehensive guidance for mana...

Sep 16th, 2020 - Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies ( 14) ]. Important Li...

Sep 15th, 2020 - To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. Data from two identically designed, 52-week, randomized st...

Sep 15th, 2020 - Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide extended-release tablets is a sulfonylurea indicated as an adjunct to diet and exerc...

Nov 13th, 2019 - A Food and Drug Administration advisory panel voted 14-2 against recommending approval of a supplemental New Drug Application for empagliflozin (Jardiance) as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes.

Aug 1st, 2019 - To the Editor: We read with great pleasure the article by Sharayah et al about acute gastro­paresis in a patient with diabetic ketoacidosis. 1 However, in the case description, the authors reached a diagnosis of gastroparesis secondary to diabetic.

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia...

Apr 25th, 2019 - LOS ANGELES – Patients with poor glycemic control, especially those with a hemoglobin A1c (HbA1c) level of more than 9%, face an increased risk for developing diabetic ketoacidosis (DKA), results from a registry study have demonstrated. Dr.

Apr 1st, 2019 - A 40-year-old man with type 1 diabetes mellitus and recurrent renal calculi presented to the emergency department with nausea, vomiting, and abdominal pain for the past day. He had been checking his blood glucose level regularly, and it had usuall.